Identification of resistance mechanisms to EGFR treatment in the real world using a clinicogenomic database Published April 2018 Citation Singal, G, Li, G, Agarwala, V, Kaushik, G, O’Connell, C, Alpha-CobbG, Caron, T, Bourque, D, Guria, A, Frank, S, Frampton, G, Carson, K, Abernethy, A.P., Miller, V.A. . AACR Annual Meeting. . https://4076230.fs1.hubspotusercontent-na1.net/hubfs/4076230/flatiron-com-pdf/AACR-2018-FH-FMI-CGDB-Poster-180411.pdf Authors: Sources:American Association for Cancer Research Annual Meeting Share Posted inPublicationsDrug discovery More publicationsASCO GUFebruary 2026Persistent gaps in BRCA mutation testing among mCRPC patients: Insights from US cancer practices (2018–2024)McKay R, Li W, Roose J, et al.Publication summaryPublicationsProstate cancerASCO GUFebruary 2026Treatment patterns and survival outcomes among lutetium 177-experienced patients with metastatic castration-resistant prostate cancertran B, Dorff T, Richey M, et al.Publication summaryPublicationsProstate cancerASCO GUFebruary 2026Opportunities for precision oncology: Real-world patterns and disparities in FGFR3 testing among US patients with locally advanced/metastatic urothelial cancerSmyth E, Richey M, Patel K, et al. Publication summaryPublicationsUrothelial cell carcinoma